Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis

Published on 17 Dec 2024 on Benzinga · via Yahoo Finance

On Monday, Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development...

Read the rest of the article

Start tracking your investments with Statfolio

The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed o...

Motley Fool · via Yahoo Finance 21 Dec 2024

Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel...

TipRanks · via Yahoo Finance 21 Dec 2024

A drug already FDA-approved for people with a rare form of breast cancer has now been shown to...

Fortune · via Yahoo News 20 Dec 2024

Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen...

Zacks · via Yahoo Finance 20 Dec 2024

It hasn't been the best quarter for Merck & Co., Inc. (NYSE:MRK) shareholders, since the share pr...

Simply Wall St. · via Yahoo Finance 20 Dec 2024

We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are go...

Insider Monkey · via Yahoo Finance 20 Dec 2024

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you mig...

Zacks · via Yahoo Finance 20 Dec 2024

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112...

FierceBiotech 18 Dec 2024

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal...

Bloomberg 18 Dec 2024

On Monday, Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development...

Benzinga · via Yahoo Finance 17 Dec 2024